The Goizueta Alzheimer’s Disease Research Center (GADRC) at the Emory Goizueta Brain Health Institute has secured a five-year, $21.9 million renewal of its P30 grant from the National Institute on Aging (NIA). The funding will support Emory’s ongoing efforts in Alzheimer’s research, clinical care, and outreach initiatives.
Emory’s GADRC, which was first designated as an NIH Alzheimer’s Disease Research Center in 2005, has become a central institution for translational research and community engagement focused on diverse populations in Georgia and the Southeast. The renewed federal grant was awarded following a competitive review process.
“We’re honored to have our center’s impact and momentum recognized with this renewal,” said Allan Levey, MD, PhD, director of the GADRC and executive director of the Emory Goizueta Brain Health Institute. “The P30 grant enables us to continue accelerating Alzheimer’s disease research and help bring advances into the clinic”.
With this continued funding, GADRC plans to focus on early detection methods and biomarker development, innovative therapies and clinical trials—including prevention strategies—precision medicine approaches for improved patient care, expanded community engagement efforts, and training programs for future researchers and clinicians.
Director Allan Levey leads the center alongside Associate Directors James Lah, MD, PhD, and Todd Golde, PhD. The GADRC collaborates with other initiatives within the Goizueta Brain Health Institute such as the Personalized Brain Health Initiative, Center for Neurodegenerative Disease, Georgia Memory Net, and Charlie and Harriet Shaffer Cognitive Empowerment Program.
“This renewal is not just an endorsement of our past work—it’s a catalyst for what comes next,” said Todd Golde. “We’re building a future where Alzheimer’s is not only treatable, but preventable.”
James Lah commented on the significance of continued NIA support: “This continued support from NIA reflects the strength of Emory’s collaborative brain health ecosystem. It enables us to push the boundaries of discovery science while also addressing real-world needs in diagnosis, treatment and equitable access to care.”
The GADRC is named after The Goizueta Foundation in recognition of its significant philanthropic contributions that have helped position Emory as a leader in brain health innovation.
The Emory Goizueta Brain Health Institute focuses on advancing prediction, prevention, and treatment methods related to brain health by developing new therapeutic strategies and biomarkers through collaborative research.
